Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

This study is currently recruiting participants.
Verified July 2012 by AVAX Technologies
Sponsor:
Information provided by (Responsible Party):
AVAX Technologies
ClinicalTrials.gov Identifier:
NCT00660101
First received: April 16, 2008
Last updated: July 10, 2012
Last verified: July 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2013
  Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)